CDK4 and breast neoplasm: In patients with advanced HR+/HER2− breast tumors, these studies examined the efficacy of combination CDK4/6i with standard endocrine therapy (an aromatase inhibitor, letrozole, or an estrogen receptor antagonist, fulvestrant).